Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

Collaboration to Accelerate T-cell Lymphoma Research

The Lymphoma Research Foundation and the Cutaneous Lymphoma Foundation announce a new strategic partnership aimed at improving the lives of all those touched by a T-cell lymphoma diagnosis.

FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl)
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

FLASH Study 2
FLASH (Fluorescent Light Activated Synthetic Hypericin) is a potential new treatment for early stage cutaneous lymphoma using visible fluorescent light pursuing a New Drug Application (NDA) filing in the United States

TELLOMAK Study
A study evaluating the efficacy and safety of a monoclonal antibody called lauctamab - alone or in combination with chemotherapy - in patients with advanced T-cell lymphoma.
Research

EORTC-CLG Annual Scientific Meeting Highlights
October 2021 - Highlights from the 2021 EORTC-CLG Scientific Meeting clinical presentations
Patient Resources

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR®
April 2020 - Helsinn Therapeutics (U.S.), Inc., the US subsidiary of the Swiss pharmaceutical group focused on building quality cancer care products, today announces a change to the financial assistance program for VALCHLOR® (mechlorethamine) gel 0.016% to ensure that commercially insured patients have access to treatment during the COVID-19 crisis.

American Society of Hematology Announces 2020 Scholar Award Recipients
December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 
Research

FDA Approves Mogamulizumab for CTCL
The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.
Research

Research in Cutaneous Lymphoma: A Broad View
Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.
Research

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides
Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.
Research

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma
For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.
Answers from the Experts

FUTURE DIRECTIONS IN T-CELL CUTANEOUS LYMPHOMA
Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.
Research

WHAT ARE FOCUS AREAS IN CUTANEOUS LYMPHOMA RESEARCH?
New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.
Research

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma
For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL.